Study of Adjuvant ONO-4538 With Resected Gastric Cancer

  • STATUS
    Not Recruiting
  • End date
    Mar 1, 2023
  • participants needed
    700
  • sponsor
    Ono Pharmaceutical Co. Ltd
Updated on 2 June 2022
gastrectomy
carcinoma
oxaliplatin
gastric adenocarcinoma
lymphadenectomy
capecitabine
gastric carcinoma
cancer chemotherapy
adenocarcinoma
adjuvant chemotherapy
tegafur
immunostimulants
gimeracil

Summary

The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.

Details
Condition Gastric Cancer
Treatment Capecitabine, Placebo, Oxaliplatin, Nivolumab, tegafur-gimeracil-oteracil potassium
Clinical Study IdentifierNCT03006705
SponsorOno Pharmaceutical Co. Ltd
Last Modified on2 June 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note